These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
391 related items for PubMed ID: 16982229
21. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. Contraception; 2011 Mar; 83(3):218-22. PubMed ID: 21310282 [Abstract] [Full Text] [Related]
22. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613 [Abstract] [Full Text] [Related]
23. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. Rome E, Ziegler J, Secic M, Bonny A, Stager M, Lazebnik R, Cromer BA. J Pediatr Adolesc Gynecol; 2004 Dec; 17(6):373-7. PubMed ID: 15603978 [Abstract] [Full Text] [Related]
24. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report. Harkins GJ, Davis GD, Dettori J, Hibbert ML, Hoyt RA. J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754 [Abstract] [Full Text] [Related]
25. [Status of bone mineral density after the long-standing application of contraception Depo-Provera]. Zeman S, Havlík P, Zemanová J, Němec D. Ceska Gynekol; 2013 Jan; 78(1):116-24. PubMed ID: 23607391 [Abstract] [Full Text] [Related]
26. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate. Modesto W, Bahamondes MV, Bahamondes L. J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552 [Abstract] [Full Text] [Related]
28. Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study. Harel Z, Wolter K, Gold MA, Cromer B, Bruner A, Stager M, Bachrach L, Hertweck P, Nelson A, Nelson D, Coupey S, Johnson CC, Burkman R, Bone H. J Pediatr Adolesc Gynecol; 2010 Aug; 23(4):209-14. PubMed ID: 20471875 [Abstract] [Full Text] [Related]
29. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover. Frost ML, Cook GJ, Blake GM, Marsden PK, Fogelman I. J Clin Densitom; 2007 Aug; 10(1):46-54. PubMed ID: 17289526 [Abstract] [Full Text] [Related]
30. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. J Pediatr Adolesc Gynecol; 2004 Feb; 17(1):17-21. PubMed ID: 15010034 [Abstract] [Full Text] [Related]
32. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Contraception; 2002 Jun; 65(6):407-10. PubMed ID: 12127638 [Abstract] [Full Text] [Related]
33. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Guilbert ER, Brown JP, Kaunitz AM, Wagner MS, Bérubé J, Charbonneau L, Francoeur D, Gilbert A, Gilbert F, Roy G, Senikas V, Jacob R, Morin R. Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668 [Abstract] [Full Text] [Related]
34. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis. Verit FF, Geyikli I, Yazgan P, Celik A. Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321 [Abstract] [Full Text] [Related]
35. Long-term depot-medroxyprogesterone acetate and bone mineral density. Tang OS, Tang G, Yip P, Li B, Fan S. Contraception; 1999 Jan; 59(1):25-9. PubMed ID: 10342083 [Abstract] [Full Text] [Related]
36. Bone density in long term users of depot medroxyprogesterone acetate. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421 [Abstract] [Full Text] [Related]
37. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T. Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538 [Abstract] [Full Text] [Related]
38. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate. Modesto W, Bahamondes MV, Silva dos Santos P, Fernandes A, Dal'Ava N, Bahamondes L. Eur J Contracept Reprod Health Care; 2014 Aug; 19(4):244-9. PubMed ID: 24923792 [Abstract] [Full Text] [Related]
39. Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, Idolazzi L, Fracassi E, Adami S. Bone; 2007 Apr; 40(4):1073-7. PubMed ID: 17240212 [Abstract] [Full Text] [Related]
40. Effects of hormonal contraception on bone mineral density after 24 months of use. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]